Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
Transition (TTHI) Stock Up on News of Acquisition by Opko
Transition Therapeutics Inc.’s shares were up 110% after the company announced that it has signed a definitive agreement under which it will be acquired by Opko Health, Inc. (OPK - Free Report) in an all-stock transaction.
Terms of the Agreement
The transaction is valued at approximately $60 million, or $1.55 per share of Transition Therapeutics common stock. Transition Therapeutics shareholders will receive approximately 6.4 million shares of Opko common stock.
The transaction is slated to close in the second half of 2016.
The deal will add Transition Therapeutics’ lead metabolic candidate, TT401, to Opko’s pipeline. TT401, a once- or twice-weekly oxyntomodulin, is being developed for the treatment of patients with type II diabetes and accompanying obesity.
Opko will add two other candidates to its pipeline – TT701 and ELND005. TT701 is being developed in a phase II study for the treatment of androgen deficiency while the company has completed phase II studies on ELND005 for the treatment of Alzheimer’s disease and Down syndrome.
Our Take
The decision to be acquired by Opko is a big and strategic deal on Transition Therapeutics’ part. With a strong pipeline, Opko will be able to offer increased value to Transition Therapeutics stockholders in the future. Moreover, Opko’s position in the market should facilitate the development of Transition’s pipeline candidates and their commercialization.
TT401 is expected to complement Opko’s existing oxyntomodulin candidate, MOD-6031, which is currently being evaluated in a phase I study.
Opko has a Zacks Rank #4 (Sell), while Transition Therapeutics carries a Zacks Rank #2 (Buy). Investors interested in the health care sector may consider Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>